Zogenix, Inc. (ZGNX) Posts Positive Phase 4 Results for Migraine Treatment
Zogenix Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, yesterday reported clinical data from its phase 4 open-label, multicenter study of SUMAVEL® DosePro ® Needle-free Delivery System for the treatment of migraines. The company demonstrated the clinical data in two poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii. "The clinical findings of this phase 4 study indicate that patients showed a greater Overall Satisfaction with subcutaneous sumatriptan delivered by SUMAVEL DosePro than their current triptan therapy, which was predominantly oral dosage…